================================================================================

                                  United States
                                   FORM 10-Q/A
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


(Mark One)

[X]             QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 1998


[  ]          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: ________________ to _______________

Commission file number:  0-5958

                       MERIDIAN MEDICAL TECHNOLOGIES, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Delaware                                     52-0898764
            --------                                     ----------
(State or other jurisdiction of                        (IRS Employer
 incorporation or organization)                      Identification No.)


10240 Old Columbia Road, Columbia, Maryland                  21046
-------------------------------------------                  -----
 (Address of principal executive offices)                  (Zip Code)
                                                       
Registrant's telephone number, including area code:      410-309-6830
                                                    
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                        YES [X]        NO [  ]

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

               Class                        Outstanding as of February 20, 1997
   ----------------------------             -----------------------------------
   Common Stock, $.10 par value                      2,935,332 Shares


================================================================================

<PAGE>

<TABLE>
<CAPTION>
                                                                                                                 Page No.
                                                                                                                 --------
<S>                                                                                                                  <C>
PART I.  FINANCIAL INFORMATION

ITEM 1.  Financial Statements (Unaudited except July 31, 1997 balance sheet)

                 Consolidated Balance Sheets as of
                    January 31, 1998 and July 31, 1997............................................................... 4

                 Consolidated Statements of Operations for
                    the Three and Six Months Ended January 31, 1998 and 1997 ........................................ 5

                 Consolidated Statements of Cash Flows for
                    the Six-Months Ended January 31, 1998 and 1997................................................... 6


                 Notes to Consolidated Financial Statements.......................................................... 7


ITEM 2.  Management's Discussion and Analysis of Financial 
                 Condition and Results of Operations................................................................. 9

PART II. OTHER INFORMATION

ITEM 4.          Submission of Matters to a Vote of Security Holders................................................ 13

ITEM 6           Exhibits and Reports on Form 8-K................................................................... 13

SIGNATURES.......................................................................................................... 14
</TABLE>


                                       2

<PAGE>


                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A

                                Explanatory Note

This Form 10-Q/A is being filed by Meridian Medical Technologies, Inc. in order
to revise upward the diluted earnings per share in the unaudited results of
operations originally reported on the Form 10-Q for the quarter and six months
ended January 31, 1998. The revision is due to a previous miscalculation of
fully diluted shares under newly required Financial Accounting Standards Board
(FASB) procedures, and does not affect basic earnings per share as previously
reported.

                                  Introduction

Meridian Medical Technologies, Inc. (hereinafter referred to as the "Company" or
"MMT" or "Meridian") was formed in November 1996 through the merger of Survival
Technology Inc. ("STI") and Brunswick Biomedical Corporation ("Brunswick"). At
the time of the merger, Brunswick held approximately 61% of STI's outstanding
common stock, which Brunswick purchased from the estate of STI's late founder on
April 15, 1996. As a result, STI had been treated for financial accounting
purposes as a consolidated, majority-owed subsidiary of Brunswick from that
date.

Although STI was the surviving corporation of the merger as a legal matter, the
merger was treated as a purchase of STI by Brunswick for financial accounting
purposes. As a result, Brunswick's historical financial statements became the
Company's financial statements, STI's assets and liabilities were revalued to
their respective fair values and the Company's historical financial statements
reflect the combined operations of STI and Brunswick after April 15, 1996
(subject to minority interests). The minority interests was eliminated upon
completion of the merger on November 20, 1996.

MMT's business plan is to operate as a medical device company focusing on Home
Healthcare and Emergency Medical Technologies. The Company has three areas of
business. The Drug Delivery Systems business capitalizes on injectable drug
delivery devices with an emphasis on commercial auto-injectors. This group also
supplies customized drug delivery system design, pharmaceutical research and
development, and sterile product manufacturing to pharmaceutical and
biotechnology companies. The Cardiopulmonary Systems business focuses on
non-invasive cardiac diagnostics and telemedicine. It is proceeding on schedule
with the research and development of the PRIME ECG(TM) program, an 80-lead
cardiac mapping system for rapid and improved diagnostic accuracy of cardiac
ischemia. The STI Military Systems business focuses on the worldwide market for
auto-injectors used by military personnel for self-administration of nerve gas
antidotes, morphine and diazepam.

Certain statements in the Quarterly Report on Form 10-Q are forward-looking and
are identified by the use of forward-looking words or phrases such as,
"believes," "expects," is or are "expected," "anticipates," "anticipated," and
words of similar import. These forward-looking statements are based on the
Company's current expectations. Because forward-looking statements involve risk
and uncertainties, the Company's actual results could differ materially. In
addition to the factors discussed generally herein, among the factors that could
cause results to differ materially from current expectations are: (i) the
general economic and competitive conditions in markets and countries where the
Company and its subsidiaries offer products and services; (ii) changes in
capital availability or costs; (iii) fluctuations in demand for certain of the
Company's products, including changes in government procurement policy; (iv)
technological challenges associated with the development and manufacture of
current and anticipated products; (v) commercial acceptance of auto-injectors
and competitive pressure from traditional and new drug delivery methods; and
(vi) delays, costs and uncertainties associated with government approvals
required to market new drugs and medical devices.


                                        3

<PAGE>

                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A


PART I. FINANCIAL INFORMATION
ITEM 1.  Financial Statements
         (in thousands of dollars)

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                January 31,                  
                                                                                   1998                   July 31, 
                                                                                (unaudited)                 1997    
                                                                                -----------                 ----    
<S>                                                                              <C>                     <C>
ASSETS                                                                                            
Current assets                                                                                    
    Cash                                                                          $     295              $      23
    Restricted cash                                                                     264                    264
    Receivables                                                                       6,684                  7,508
    Inventories                                                                       8,541                  6,046
    Prepaid expenses and other assets                                                   416                    531
    Deferred income taxes                                                             1,659                  1,659
                                                                                  ---------              ---------
         Total Current Assets                                                        17,859                 16,031
                                                                                  ---------              ---------
                                                                                                  
Fixed assets                                                                         18,749                 17,246
    Less accumulated depreciation                                                     2,463                  1,468
                                                                                  ---------              ---------
                                                                                     16,286                 15,778
                                                                                  ---------              ---------
                                                                                                  
Excess of cost over net assets acquired                                               8,636                  9,168
Other intangible assets                                                               2,879                  3,105
                                                                                  ---------              ---------
                                                                                  $  45,660              $  44,082
                                                                                  =========              =========
                                                                                                  
LIABILITIES AND SHAREHOLDERS' EQUITY                                                              
Current liabilities:                                                                              
    Accounts payable and other accrued liabilities                                $   8,188              $   7,733
    Lines of credit                                                                   4,689                  4,113
    Current portion of long-term debt                                                 2,536                  2,299
    Customer deposits                                                                   687                    918
    Restructuring reserve                                                               123                    124
                                                                                  ---------              ---------
         Total Current Liabilities                                                   16,223                 15,187
                                                                                                  
Long-term debt:                                                                                   
    Notes payable                                                                    12,646                 13,062
    Other long-term debt                                                                640                    859
    Deferred revenue                                                                                           315
    Other noncurrent liabilities                                                        712                    625
    Deferred income taxes                                                             1,741                  1,741
                                                                                  ---------              ---------
         Total Liabilities                                                           31,962                 31,789
                                                                                  ---------              ---------
                                                                                             
Shareholders' equity
    Common stock $.10 par, 18,000,000 authorized,  2,935,332 and
     2,912,502 issued and outstanding                                                   294                    291
    Paid-in capital                                                                  28,734                 28,660
    Warrants                                                                          2,073                  2,073
    Accumulated deficit                                                             (17,058)               (18,312)
    Unearned stock option compensation                                                 (139)                  (139)
    Foreign currency translation adjustment                                               7                    (67)
    Treasury stock, at cost                                                            (213)                  (213)
                                                                                  ---------              ---------
    Total shareholders' equity                                                       13,698                 12,293
                                                                                  ---------              ---------
                                                                                  $  45,660              $  44,082
                                                                                  =========              =========
</TABLE>

          See accompanying notes to consolidated financial statements.


                                       4

<PAGE>

                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A

                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)
                (in thousands of dollars, except per share data)


<TABLE>
<CAPTION>
                                                            Three-Months Ended                      Six-Months Ended
                                                                January 31,                            January 31,
                                                         1998                1997               1998                1997
                                                         ----                ----               ----                ----
<S>                                                  <C>                <C>                 <C>                 <C>         
Net sales                                            $     10,723        $      8,787       $     21,366        $     18,984
Cost of sales                                               6,388               5,552             12,896              11,969
                                                     ------------        ------------        -----------        ------------

     Gross profit                                           4,335               3,235              8,470               7,015

Selling, general & administrative expense                   1,569               1,319              2,941               2,875
Research & development expense                                409                 627                775               1,656
Depreciation and amortization expense                         874                 744              1,765               1,447
Write-off in-process R&D                                       --               2,702                 --               2,702
Write-off merger transaction costs                             --               1,246                 --               1,246
                                                     ------------        ------------        -----------        ------------
                                                            2,852               6,638              5,481               9,926

Operating income (loss)                                     1,483              (3,403)             2,989              (2,911)
Other expense (income)
     Interest expense                                         676               1,092              1,389               1,606
     Other income                                            (186)                (10)              (194)               (124)
                                                     ------------        ------------        -----------        ------------
                                                              490               1,082              1,195               1,482

Income (loss) before income taxes                             993              (4,485)             1,794              (4,393)
Provision (benefit) for income taxes                          354                 (48)               540                 367
Minority interest in consolidated subsidiary                   --                   9                 --                 265
                                                     ------------        ------------        -----------        ------------


Net income (loss)                                    $        639        $     (4,446)       $     1,254        $     (5,025)
                                                     ============        ============        ===========        ============

Net income (loss) per share:
     Basic                                           $        .22        $     (2.24)        $       .43        $      (4.95)
                                                     ============        ===========         ===========        ============
     Diluted                                         $        .19        $     (2.24)        $       .38        $      (4.95)
                                                     ============        ===========         ===========        ============

Weighted average shares:
     Basic                                              2,919,451          1,988,025           2,917,250           1,016,305
     Diluted                                            3,273,182          1,988,025           3,258,525           1,016,305
</TABLE>



          See accompanying notes to consolidated financial statements.

                                       5

<PAGE>

                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
                            (in thousands of dollars)

<TABLE>
<CAPTION>
                                                                                       Six Months Ended
                                                                                         January 31,
                                                                             1998                            1997
                                                                             ----                            ----
<S>                                                                     <C>                               <C>
Cash flows from operating activities:
   Net income (loss)                                                    $       1,254                    $    (5,025)
   Adjustments to reconcile net income (loss) to net cash
     provided  by operating activities
     Depreciation and amortization                                              1,765                          1,445
     Amortization of deferred compensation                                         37                             36
     Amortization of notes payable discount                                       584                            882
     Loss (gain) on fixed asset disposals                                          22                             (7)
     Write off in-process R&D                                                      --                           2702
   Changes in assets and liabilities
     Receivables                                                                  824                            206
     Inventories                                                               (2,495)                          (570)
     Prepaid expenses and other assets                                            115                            158
     Accounts payable and accrued liabilities                                     492                          1,905
     Restructuring reserve                                                         (1)                          (323)
     Other liabilities and accrued expenses                                      (231)                          (580)
     Deferred revenue                                                            (315)                           128
     Other noncurrent assets                                                       --                           (338)
     Other noncurrent liabilities                                                  87                             42
                                                                        -------------                    -----------
         Net cash provided by operating activities                              2,138                            661
                                                                        -------------                    -----------

Cash flows from investing activities:
   Purchases of fixed assets                                                   (1,537)                        (1,381)
   Purchases of patents and licenses                                               --                            (25)
   Increase in short-term investments                                              --                             (3)
   Proceeds from sale of fixed assets                                              --                              3
                                                                        -------------                     ----------
         Net cash (used for) investing activities                              (1,537)                        (1,406)
                                                                        =============                     ===========

Cash flows from financing activities:
   Proceeds from line of credit                                                   576                          1,340
   (Net payment) on notes payable long-term                                      (750)                        (1,400)
   (Net payment) on other long-term debt                                         (232)                           (70)
   Proceeds from issuance of common stock                                          77                             --
                                                                        -------------                    -----------

         Net cash (used for) financing activities                                (329)                          (130)
                                                                        -------------                    -----------

Net increase (decrease) in cash                                                   272                           (875)
   Cash at beginning of period                                                     23                          1,489
                                                                        -------------                    -----------
   Cash at end of period                                                $         295                    $       614
                                                                        =============                    ===========
</TABLE>


          See accompanying notes to consolidated financial statements.

                                       6



<PAGE>


                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.       In the opinion of management, the accompanying unaudited consolidated
         financial statements contain all adjustments (consisting of normal
         recurring accruals) necessary to present fairly the Company's financial
         position as of January 31, 1998 and July 31, 1997, the results of its
         operations for the three-month and six-month periods ended January 31,
         1998 and 1997, and its cash flows for the six-month periods ended
         January 31, 1998 and 1997. The results of operations for the
         three-month and six-month periods ended January 31, 1998 are not
         necessarily indicative of the results that may be expected for the
         fiscal year ending July 31, 1998.

2.       On November 20, 1996, Brunswick Biomedical Corporation ("Brunswick")
         was merged into Survival Technology, Inc. ("STI") to form Meridian
         Medical Technologies, Inc. ("MMT" or the "Company"). At the time of the
         merger, Brunswick held approximately 61% of STI's outstanding common
         stock, which it had purchased from the estate of STI's late founder on
         April 15, 1996. As a result, STI had been treated for financial
         accounting purposes as a consolidated, majority-owned subsidiary of
         Brunswick from that date and Brunswick's historical financial
         statements became the Company's financial statements, STI's assets and
         liabilities have been revalued to their respective fair values and
         Brunswick's historical financial statements reflect the combined
         operations of STI and Brunswick after April 15, 1996 (subject to
         minority interests). The minority interests were eliminated upon
         completion of the merger on November 20, 1996. (See Meridian's Annual
         report on Form 10-K for fiscal year ended July 31, 1997 for a more
         complete discussion of the merger accounting.)

3.       Inventories consisted of the following:

<TABLE>
<CAPTION>
                                                             January 31,                      July 31,
                                                                1998                            1997
                                                                ----                            ----
<S>                                                          <C>                             <C>       
         Components and subassemblies                        $   7,560                       $   4,788
         Material, labor and overhead
             costs in process                                    1,206                           1,460
            Finished goods                                         320                             345
                                                             ---------                       ---------
                                                             $   9,086                       $   6,593

         Inventory reserve                                        (545)                           (547)
                                                             ---------                       ---------
         Total                                               $   8,541                       $   6,046
                                                             =========                       =========
</TABLE>




                                       7


<PAGE>

                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)


4.       On October 8, 1997, the Company announced a product exchange program
         for all of its EpiEZPen(R) product sold since March 1996 (approximately
         500,000 units). This exchange program was initiated after a minimal
         amount of units (less than 10 units) were returned for premature
         activation in the package. Management performed an analysis of
         potential costs of the exchange program and made their best estimate
         regarding these costs. The estimated cost of the exchange program is
         $1.5 million and was included in fiscal 1997 results of operations as
         reported in the Company's Annual Report on Form 10-K. Actual costs
         could differ materially from management's estimates; however, it now
         appears that the reserve will be adequate. The Company has not included
         any anticipated cost sharing of this exchange with potentially
         responsible parties as the benefit and probability of such an
         arrangement are not determinable at this time. Actual costs incurred
         through January 31, 1998 were approximately $541,000. The Company
         believes the exchange will be substantially complete by the end of
         fiscal 1998.

5.       In February 1997, the Financial Accounting Standards Board issued
         Statement No. 128, Earnings per Share, which is required to be adopted
         by the Company in its January 1998 financial statements. The Company
         has adopted this methodology and used it to compute current earnings
         per share and to restate all prior periods. Under the new requirements
         for calculating basic earnings per share, the dilutive effect of stock
         options, warrants and other potentially dilutive common shares are
         excluded. Fully diluted EPS has not changed significantly but has been
         renamed diluted EPS.





                                       8

<PAGE>


                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A


ITEM 2.  Management's Discussion and Analysis of Financial Condition and
         Results of Operations

The Quarter and Six Months in Review

MMT reported a net income of $639,000, $0.22 basic earnings per share or $0.19
diluted earnings per share (see Footnote 5 in financial statements) on sales of
$10.7 million for the second quarter of 1998 ended January 31, 1998 compared
with a net loss of ($4.4 million) or ($2.24) basic and diluted earnings per
share, on sales of $8.8 million in the same period of fiscal 1997. The fiscal
1997 shares shown in the financials are not comparable to fiscal 1998 due to the
low share base of Brunswick prior to the merger. The fiscal 1997 net loss for
the three months ended January 31, 1997 included $3.9 million of merger related
costs. Earnings before interest, taxes, depreciation and amortization (EBITDA)
for the second quarter of fiscal 1998 was $2.5 million compared to $1.3 million
(excluding merger costs) for the same period in fiscal 1997.

For the first six-months ended January 31, 1998 MMT reported net income of $1.3
million or $0.43 basic earnings per share and $0.38 diluted earnings per share
on revenues of $21.4 million. These results compare to a net loss of ($5.0
million) or ($4.95) per basic and diluted share for the fiscal 1997 six-month
comparable period. EBITDA for the first six months of the fiscal 1998 was $4.9
million compared to $2.6 million (excluding merger costs) in the same period of
fiscal 1997.

Gross profit and revenues of MMT's three areas of business for the quarter and
six-months ended January 31, 1998 and 1997 are as follows:

<TABLE>
<CAPTION>
                                              Quarter ended                                   Six Months ended
        ($thousands)             January 31, 1998        January 31, 1997         January 31, 1998        January 31, 1997
                                 ----------------        ----------------         ----------------        ----------------
<S>                                <C>                    <C>                      <C>                     <C>          
Drug Delivery                      $       6,310          $       3,997            $      11,396           $       9,141
Cardiopulmonary                              293                    607                      530                   1,547
STI Military  Systems                      4,120                  4,183                    9,440                   8,296
                                   -------------          -------------            -------------           -------------

Total Revenues                     $      10,723          $       8,787            $      21,366           $      18,984
                                   =============          =============            =============           =============

Gross Profit                       $       4,335          $       3,235            $       8,470           $       7,015
                                   =============          =============            =============           =============

Gross Profit %                              40.4%                  36.8%                    39.6%                   36.9%
</TABLE>

Revenue in the Drug Delivery business was $6.3 million in the three month period
ended January 31, 1998 compared to $4.0 million for the same period of fiscal
1997, a 58% increase. The higher revenues in fiscal 1998 second quarter compared
to fiscal 1997 is due to higher EpiPen(R) family of product revenues. These
revenues were 92% higher in the current quarter compared to the same period as
last year reflecting generally higher demand coupled with a benefit from a build
up of inventory at the Company's distributor Dey Laboratories.

Drug Delivery revenues for the first six-months of fiscal 1998 have increased by
25% to $11.4 million over the comparable period in the prior year. This increase
is attributable primarily to the aforementioned growth in the EpiPen(R) family
of products.


                                       9

<PAGE>

                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A


Management's Discussion and Analysis of Financial Condition and
Results of Operations (Continued)

The Company anticipates epinephrine product sales to continue improving over
prior year levels with Dey's continued expansion of marketing efforts in the
U.S. and international markets.

Cardiopulmonary revenues were down in the second quarter and six-months ended
January 1998 compared to the same periods of fiscal 1997 primarily due to the
sale of a non-core emergency care product line previously included as part of
the cardiopulmonary business and absence of CardioBeeper(R) promotion held in
fiscal 1997. The majority of sales in fiscal 1998 were CardioBeepers(R). The
Company is in ongoing discussions with a potential strategic partner to market
the Cardiobeeper(R) CB-12L cardiac monitor in the U.S. where the product
recently received clearance by the FDA.

The Cardiopulmonary systems group PRIME ECG(TM) product development is
proceeding on schedule towards a FY99 European launch and FY00 U.S. launch.
Several potential U.S. partners have been identified although no assurances can
be made that agreements will be reached or timetables achieved.

STI Military Systems revenues in the second quarter of fiscal 1998 were $4.1
million, essentially equal to the same period last year. Revenue for the first
six-months was $9.4 million, up 14% over the same period in the prior year. This
year-to-date growth is attributable to increased auto-injector sales to allied
foreign governments.






                                       10

<PAGE>


                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A


Management's Discussion and Analysis of Financial Condition and
Results of Operations (Continued)

Gross profits were 40.4% and 39.6% of revenues in the second quarter and
six-months ended January 31, 1998, respectively. These percentages compare to
36.8% and 36.9% in the same periods of fiscal 1997. This margin improvement is
due to the increased revenues and continuing cost reduction programs.

Operating costs were $2.9 million for the second quarter of fiscal 1998 compared
to $2.7 million (excluding merger-related costs) in the same period of fiscal
1997. For the first six-months of fiscal 1998 operating costs were $5.5 million
as compared to $6.0 million (excluding merger related costs) in the same period
of fiscal 1997. This decline in operating cost year-to-year is associated with
cost reduction programs implemented after the merger and lower bad debt expense
offset partially by an increase in investor relations spending and legal costs
related to normal business activities. Interest expense was $676,000 for the
second quarter compared to $1.1 million in the same period of fiscal 1997. The
higher interest costs in the prior year were associated with an over accrual of
estimated merger interest in the second quarter which was corrected in third
quarter, fiscal 1997.

The provision for income taxes in the second quarter and first six-months of
fiscal 1998 reflects the benefits of utilizing the net operating loss
carryforwards of Brunswick available for use subsequent to the merger. A tax
provision for first six months of fiscal 1997 exists because the Company needed
to provide for taxes on STI earnings but could not realize the benefit from
losses incurred by Brunswick.

Liquidity and Capital Resources

Total cash as of January 31, 1998 was $559,000, an increase of $272,000 from
prior year ended July 31, 1997. The Company generated $2.1 million of cash from
operations in the first six-months of fiscal 1998. This generation of cash was
attributable to the net profits, plus non-cash depreciation and amortization,
offset by cash used to fund working capital changes primarily inventory for the
DoD pre-stock order. Investing activities in the first half of fiscal 1998 used
$1.5 million of cash for capital additions. The majority of capital was for
automation equipment associated with cost reduction projects and for a new
autoclave used in the production operation in St. Louis. Financing activities
required payment of $750,000 on the long-term debt with International
Nederlanden (U.S.) Capital Corporation ("ING") which was partially offset by
borrowings under the working capital line and proceeds from issuance of common
stock on options exercised.

During the six months ended January 31, 1998, the Company increased its asset
based working capital credit line with ING CAPITAL to a maximum of $6.5 million
from $5.0 million. The amount outstanding under this working capital line at
January 31, 1998 was $4.4 million. The Company has engaged ING CAPITAL to
restructure the existing ING CAPITAL term loan. The structure of the new debt
will be some form of mezzanine financing. It is anticipated the new debt will be
in place by the fourth quarter fiscal 1998. This refinancing may result in an
approximate $1.5 million ($0.9 million after tax) non-cash, extraordinary charge
for restructuring of debt. The extraordinary charge will not affect operating
income or gross margins and will not distort the core financial measures of the
Company. No assurances can be made that the Company will be successful in this
effort and a delay in such restructuring could have an adverse effect on the
Company's liquidity. However, management believes existing financing sources and
other actions available, such as reducing discretionary spending on research and
development, capital expenditures and other costs if necessary, will enable it
to meet its financing obligations through the next 12 months.

                                       11

<PAGE>

                      MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                  FORM 10-Q/A


Management's Discussion and Analysis of Financial Condition and
Results of Operations (Continued)

Working capital at January 31, 1998 was $1.6 million, up from $0.8 million at
July 31, 1997. The increase is primarily attributable to higher inventories
($2.5 million) offset partially by decreased receivables ($0.8 million) and
higher accounts payable ($0.5 million). Accounts receivable were $6.7 million
representing 55 days-sales-outstanding. Component, work in process and finished
goods inventories (net) were $8.5 million up $2.5 million from the balance at
July 31, 1997 due primarily to receipts of the majority of DoD pre-stock
inventory which will be sold in third quarter of fiscal 1998. Accounts payable
at the end of the second quarter of fiscal 1998 was $8.2 million, up $0.5
million from the balance at July 31, 1997 driven by the timing of delivery of
DoD pre-stock inventory. Borrowings under working capital lines were $4.7 at
January 31, 1998.



                                       12

<PAGE>



PART II - OTHER INFORMATION

ITEM 4.  Submission of Matters to a Vote of Security Holders.

The Company held its annual meeting of stockholders on December 11, 1997 (the
"Annual Meeting"). A total of 2,404,918 shares of common stock were voted at the
Annual Meeting in person or by proxy. The stockholders voted to reelect E.
Andrews Grinstead, III as a director with 2,252,327 votes cast for the nominee
and 0 votes cast against or withheld. The stockholders also voted to approve the
Company's 1997 Long-Term Incentive Plan with 1,268, 002 votes cast for approval,
202,259 votes against or withheld, and 26,625 abstentions and broker-nonvotes.
Finally, the stockholders voted to ratify the selection by the Board of
Directors of Ernst & Young LLP as independent auditors of the Company for the
fiscal year with 2,167,925 votes cast for ratification, 232,373 votes against or
withheld, and 4,620 abstentions or broker-nonvotes.

ITEM 6.  Exhibits and Reports on Form 8-K:

(b)      Reports on Form 8-K

         No reports on Form 8-K were filed during the three months ended January
         31, 1998.





                                       13

<PAGE>



                                   SIGNATURES


Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                         MERIDIAN MEDICAL TECHNOLOGIES, INC.
                                           Registrant


           March 26, 1998                By:   /S/ James H. Miller
           --------------                      -----------------------------
                Date                           James H. Miller              
                                               President and                
                                               Chief Executive Officer      
                                               (Principal Executive Officer)
                                               


           March 26, 1998                By:   /S/ G. Troy Braswell
           --------------                      -----------------------------
                Date                           G. Troy Braswell             
                                               Vice President-Finance       
                                               and Chief Financial Officer  
                                               (Principal Financial and     
                                               Accounting Officer)          
                                               


                                       14